Aymen Abdalkader Shaibatalhamd Discloses 5.9% Stake in CorMedix Inc. (CRMD)

Aymen Abdalkader Shaibatalhamd, an individual investor based in Saudi Arabia, filed a Schedule 13G/A on June 12, 2026, regarding his holdings in CorMedix Inc. (CRMD). The filing indicates that as of the event date on June 11, 2026, Shaibatalhamd beneficially owns 4,618,511 shares of CorMedix's common stock. This represents approximately 5.9% of the company's outstanding shares. The filing is an amendment (Amendment No. 4) and specifies that the reporting person has sole voting and dispositive power over all reported shares. This position marks an increase from the previously recorded 0.0% ownership, establishing Shaibatalhamd as a significant passive investor in the New Jersey-based pharmaceutical company. The shares are held directly by the individual, who is a citizen of Saudi Arabia. CorMedix Inc. is known for its focus on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.